- Report
- April 2025
- 200 Pages
Global
From €2266EUR$2,490USD£1,943GBP
- Report
- April 2025
- 172 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- January 2025
- 133 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Drug Pipelines
- March 2025
- 80 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- June 2024
- 266 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- June 2024
- 122 Pages
Europe
From €1365EUR$1,500USD£1,170GBP
- Report
- September 2023
- 170 Pages
Global
From €1811EUR$1,990USD£1,553GBP
- Report
- November 2023
- 145 Pages
Global
From €4050EUR$4,450USD£3,472GBP
- Report
- August 2022
- 106 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- June 2022
- 85 Pages
Global
From €3185EUR$3,500USD£2,731GBP
- Report
- November 2021
- 844 Pages
Global
From €4551EUR$5,000USD£3,901GBP

Huntingtin is a protein found in the central nervous system (CNS) that is associated with Huntington's disease, a rare, inherited neurological disorder. The Huntingtin market is a subset of the CNS drugs market, which is focused on developing treatments for neurological disorders. The Huntingtin market is composed of companies that are researching and developing drugs to treat Huntington's disease. These drugs are designed to reduce the production of the mutated Huntingtin protein, which is responsible for the symptoms of the disease.
The Huntingtin market is a relatively small market, but it is growing as more companies enter the space. Companies in the Huntingtin market include Ionis Pharmaceuticals, Roche, Novartis, and Sanofi. These companies are researching and developing drugs to treat Huntington's disease, as well as other neurological disorders. Show Less Read more